Recursion acquires Exscientia in stock deal; director Burrell resigns; Q2 results reported

RECURSION PHARMACEUTICALS, INC.

Recursion to acquire Exscientia via UK scheme of arrangement; Exscientia shareholders get 0.7729 Recursion shares per share.
Termination fees: Exscientia pays $6.88M if it accepts a superior proposal; Recursion pays $58.77M if it walks.
Terry-Ann Burrell resigns from board effective Aug 12, 2024; Zachary Bogue appointed Audit Committee Chair.
Q2 2024 financial results announced; specific figures not provided in this filing but refer to press release.

item 1.01 item 2.02 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Terry-Ann Burrell

Director and Chair of Audit Committee

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2024-08-12
Successor: Zachary Bogue
Filed: August 8, 2024, 7:59 PM ET

On August 6, 2024, Terry-Ann Burrell informed the Company’s board of her decision to resign as a member of the Company’s board and Chair of its Audit Committee, effective August 12, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Terry-Ann Burrell resigned as Director and Chair of Audit Committee at RECURSION PHARMACEUTICALS, INC..

Action: resigned
Role: Director and Chair of Audit Committee

Exact text from the filing

On August 6, 2024, Terry-Ann Burrell informed the Company’s board of her decision to resign as a member of the Company’s board and Chair of its Audit Committee, effective August 12, 2024.

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-196505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.